Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

VolitionRX Limited

Name: FDA Catalyst: Example Drug
Start: 2026

$0.35

-0.03 (-8.45%)

Market Cap

4.21 M

EPS

-2.00

P/E Ratio

Value Trade

267.59 K

-28.43 %

Week

-60.3 %

1 Month

-88.12 %

3 Month

-92.82 %

6 Month

-95.58 %

5 Year

-60.88 %

All Time

Cash Data

Cash Position
-
Monthly Burn
-
Runway
-

Overview

Volume

26.54 M

52 Week Range

0.37 - 14.80

% held by Insiders

11.01 %

% held by Institutions

14.15 %

Enterprise Value

9.68 M

Total Shares

12.04 M

Short %

4.43 %

Float Shares

6.54 M

Company Description

HQ: 1489 WEST WARM SPRINGS ROAD, H...

Founded:02-03-2012

Employees:75

https://www.volition.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology

Unlock Upcoming Catalyst data

Unlock the full Catalyst Timeline

Past FDA Catalysts & PDUFA Decisions

Date	Drug	Catalyst	Stage	Outcome	Reaction	Event Move %	Best Trade %
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%

Unlock Historical Catalyst data

Drug Pipeline Intelligence

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
Nu.Q® Cancer	Non Small Cell Lung Cancer	—	2026-03-26	high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes; low H3K27me3 levels indicated significantly better outcomes Read More	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Read More
Nu.Q® Cancer	Non Small Cell Lung Cancer	—	2026-03-26	high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes; low H3K27me3 levels indicated significantly better outcomes Read More	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Read More
Nu.Q® Cancer	Non Small Cell Lung Cancer	—	2026-03-26	high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes; low H3K27me3 levels indicated significantly better outcomes Read More	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in VNRX

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

VNRX Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv
2026-09-18		0	0.00		0	0	-	-	-	-	-	-
2026-09-18		0	0.00		0	0	-	-	-	-	-	-
2026-09-18		0	0.00		0	0	-	-	-	-	-	-

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

VolitionRx Limited has announced a conference call scheduled for August 14, 2026, to discuss its second quarter financial results and provide a business update. The call will feature key executives, including the Group Chief Executive Officer and Chief Financial Officer. The company aims to highlight important events and milestones achieved in the quarter.

-VNRX

Aug 5, 2026

VNRXGeneral

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

VolitionRx Limited has published its first peer-reviewed paper on Capture-Seq, a novel liquid biopsy technology that isolates over 99% pure circulating tumor-derived DNA. This breakthrough addresses a major challenge in liquid biopsy methods, potentially revolutionizing early cancer detection and minimal residual disease monitoring. The company is actively pursuing commercialization discussions with global diagnostic leaders.

-VNRX

Jul 30, 2026

VNRXGeneral

Volition Advances Nu.Q® NETs Platform Towards Commercialization

VolitionRx Limited has announced advancements in its Nu.Q® NETs platform, which is positioned as a potential breakthrough in sepsis management. The company highlighted substantial clinical and scientific data supporting the product's effectiveness. The Nu.Q® H3.1 operates within a significant $3.8 billion market, indicating strong commercial potential.

-VNRX

Jul 7, 2026

VNRXFDA Updates

VolitionRx Limited has filed a new patent for its Nu.Q technology aimed at triaging and monitoring potential Ebola cases. This innovative approach focuses on the host's immune response instead of merely identifying the virus. The company is actively seeking strategic partners for trials and deployment in outbreak areas, emphasizing its potential impact in low-resource healthcare settings. The ongoing Ebola outbreaks underline the need for improved early detection methods, making Volition's advancements timely and critical.

-VNRX

May 28, 2026

VNRXGeneral

Volition has submitted a manuscript for peer review detailing the Nu.Q® Vet Feline assay, which shows 97% specificity and 86% sensitivity in detecting lymphoma in cats. This test aims to fill a critical gap in feline oncology by providing a simple, affordable blood-based liquid biopsy. The publication is expected to unlock a $5 million milestone payment, highlighting the commercial potential of the technology.

-VNRX

Apr 29, 2026

VNRXGeneral

Cell Death White Paper, Nu.Q® Discover

The Nu.Q® Discover Cell Death white paper presents the Nu.Q® H3.1 immunoassay, designed to quantify cell death by measuring circulating nucleosomes. These nucleosomes, released during apoptosis, necrosis, and NETosis, serve as stable biomarkers. The assay is versatile, applicable to diverse biological samples such as plasma and cell culture supernatants.

-VNRX

Apr 29, 2026

VNRXGeneral

▼ -5%on this newsshared move

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Limited has achieved a significant technical milestone by successfully detecting nucleosomes in capillary blood from sepsis patients using a lateral flow prototype. This innovative finger-prick testing method can be applied in various settings, including emergency rooms and home testing, potentially transforming sepsis diagnostics. The company aims to address unmet diagnostic needs with a cost-effective solution, targeting expansion into low-income countries and enhancing patient outcomes through rapid decision-making capabilities.

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

VolitionRx Limited announced that its compliance plan was accepted by the NYSE American, allowing the company to retain its listing on the exchange. This decision is a response to a prior notification regarding non-compliance with listing standards due to insufficient stockholders' equity. The company has until August 6, 2027, to regain compliance, subject to periodic evaluation by the NYSE American. The company's listing remains unaffected during this compliance period, ensuring its ongoing business operations continue as normal.

-VNRX

Apr 20, 2026

VNRXGeneral

▼ -8.7%on this news· ran to -19% by day 3shared move

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited has launched its rNuQ webshop, offering a range of recombinant nucleosomes for research. This initiative aims to enhance accessibility for researchers and is part of Volition's strategy to commercialize its products. The nucleosomes are manufactured under strict quality controls, and the company anticipates continued revenue growth in the coming year.

VolitionRx krijgt 2,0 miljoen EUR aan niet-verwaterende financiering van regionale overheidsinstanties in BelgiëNederland - NederlandsUSA - EnglishFrance - Français

VolitionRx Limited has obtained an additional €2 million in non-dilutive funding from Namur Invest and Wallonie Entreprendre S.A. in Belgium. The funds will be used to advance their Nu.Q® product portfolio and regulatory transition program. This funding marks a significant milestone in Volition's financing strategy, bringing their total non-dilutive funding to over $25 million.

-VNRX

Apr 1, 2026

VNRXGeneral

VolitionRx Limited announced its financial results and business updates for the fiscal year 2025, highlighted by a 40% increase in revenue and a 133% growth in Q4. The company has begun clinical certification for its Nu.Q Cancer assays and is involved in a government-backed sepsis detection program worth approximately $7.3 million. Despite these successes, the company reported a net loss decrease of 14%, emphasizing ongoing financial challenges. A conference call is scheduled for April 1, 2026, to discuss these results and future milestones.

-VNRX

Mar 30, 2026

VNRXPhases

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

VolitionRx Limited has published a clinical study in the Shock Journal revealing that its Nu.Q® biomarkers, specifically levels of H3.1 and H3R8 Citrulline, are significantly elevated in trauma patients. The study, conducted by a team at Mayo Clinic, analyzed 674 trauma cases, indicating that these levels are especially high among patients who develop complications such as Venous Thromboembolism. This research highlights the potential for Nu.Q® biomarkers to aid in early risk identification and guide treatment strategies in trauma care. The publication supports Volition’s ongoing efforts to commercialize their diagnostic products.

-VNRX

Mar 26, 2026

VNRXConferences/Events

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

VolitionRx Limited presented an abstract at the European Lung Cancer Conference, showcasing its Nu.Q® Cancer assays for managing lung cancer. The study revealed that measuring H3K27Me3-nucleosomes can help identify Non Small Cell Lung Cancer patients who may benefit from closer monitoring or secondary treatments. This advancement aims to enhance precision in treatment selection and improve patient outcomes.

-VNRX

Mar 25, 2026

VNRXConferences/Events

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

VolitionRx Limited has scheduled a conference call for April 1, 2026, to discuss its financial and operational results for the fiscal year 2025. The call will feature key executives, including the CEO and CFO, who will provide updates on significant events and future milestones. A live audio webcast will also be available for interested parties.

-VNRX

Mar 25, 2026

VNRXGeneral

▼ -10.9%on this newsshared move

Video: Transcription Factor DNA in Plasma New Data Revealed

The article discusses new data regarding the prognostic value of the Nu.Q® cancer test and its relevance in assessing transcription factor DNA in plasma. It highlights related research on cytokine-induced chromatin accessibility in neutrophils and its connection to sepsis. The content suggests ongoing developments in cancer diagnostics and related fields.

-VNRX

Mar 25, 2026

VNRXGeneral

Volition Announces Detection of Over 95% of Early-Stage Cancers

VolitionRx Limited has announced promising proof of concept data demonstrating its Capture-Seq™ technology's ability to detect over 95% of early-stage cancers. This breakthrough could revolutionize cancer diagnosis, offering a significant advancement in early detection methods. The announcement was made by Dr. Jake Micallef, the Chief Scientific Officer of Volition.

-VNRX

Mar 25, 2026

VNRXGeneral

VolitionRx Limited announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA (ctDNA). This novel method, termed Capture-Seq™, shows promise for early detection of multiple cancers and the detection of minimal residual disease. Initial clinical validation results report no false positives and successful cancer detection in both early and later stages. The company is in discussions with diagnostic leaders to accelerate commercialization, targeting a significant total addressable market estimated at $36 billion.

-VNRX

Mar 11, 2026

VNRXConferences/Events

Join Volition Veterinary at Netherlands Vet

Volition Veterinary is inviting veterinary professionals to connect at the Netherlands Vet event. The focus will be on the Nu.Q® Vet Cancer Test for dogs, emerging data for felines, and advancements in epigenetic biomarkers. Attendees can access various resources to integrate these innovations into their practices.

-VNRX

Mar 6, 2026

VNRXGeneral

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

VolitionRx Limited (VNRX) has announced the successful validation of the automated version of its Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems in Japan. This innovation will enhance the testing process by allowing full automation in laboratories, moving away from manual plates. The test has already generated significant interest among Japanese veterinarians, with over 1,700 veterinary hospitals registered to utilize the technology. The collaboration opens up substantial revenue opportunities, particularly in a market with approximately seven million pet dogs in Japan, where early cancer detection can lead to better health outcomes.

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

VolitionRx Limited has announced substantial clinical and commercial advancements, including the submission of a manuscript on a novel cancer detection method, Capture-Seq™. The company is preparing for a reimbursement submission for its Nu.Q® Cancer assays in lung cancer, aiming for routine clinical use by late 2026. Additionally, VolitionRx is involved in a government-funded study for early sepsis detection and has reported promising results for its veterinary cancer assays.

-VNRX

Feb 18, 2026

VNRXGeneral

Introducing Nu.Q® NETs: Precision Biomarker Across Acute and Chronic Care.

Nu.Q® NETs is a novel biomarker-driven solution aimed at improving patient care by enabling clinicians and researchers to better anticipate disease progression and make informed treatment decisions. This tool is applicable for both acute and chronic conditions, promoting personalized approaches to healthcare. The introduction of Nu.Q® NETs signifies a step forward in precision medicine.

VolitionRx Limited is preparing a reimbursement submission for its Nu.Q® Cancer assays, supported by Hospices Civils de Lyon. The goal is to integrate the test into routine clinical practice for lung cancer management in France. This initiative is expected to enhance precision in treatment selection and monitoring, with hopes for implementation by late 2026.

-VNRX

Jan 27, 2026

VNRXGeneral

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

VolitionRx Limited has announced a new clinical study demonstrating the effectiveness of its Nu.Q® NETs assay in managing Hidradenitis Suppurativa (HS), a chronic disease affecting about 1% of the global population. The assay is CE-Marked and approved for clinical use in several European regions. The study highlights the potential for personalized treatment approaches and indicates a significant market opportunity for the assay.

-VNRX

Jan 22, 2026

VNRXGeneral

Utilizing the Nu.Q®Vet Cancer Test in Practice: VMX 2026 presentation with Dr. Sue Cancer Vet

Volition has announced the submission of a manuscript for its Nu.Q® Vet Cancer Test in cats, which is expected to unlock a $5 million milestone payment upon publication. Additionally, the company has developed the first automated version of the test in collaboration with Fujifilm Vet Systems. These developments were highlighted in a presentation at VMX 2026 by Dr. Sue Cancer Vet.

-VNRX

Jan 20, 2026

VNRXGeneral

▲ +8.4%on this newsshared move

The London Vet Show 2025 will feature two sessions led by Dr. Tom Butera, CEO of Volition Veterinary, focusing on early cancer detection in dogs. The talks will cover the practical applications of the Nu.Q® Vet Cancer Test in clinical settings, emphasizing its role in routine screening and preventive care. Attendees will gain insights on integrating this innovative tool into their practices.

-VNRX

Nov 17, 2025

VNRXGeneral

Veterinary resources – in clinic (UK/EU)

Volition is launching a range of educational materials to promote the Nu.Q® Vet Cancer Test aimed at pet parents in the UK and EU. These materials include posters, brochures, and social media assets that highlight the importance of early canine cancer screening. Additionally, the company has announced a significant milestone related to the test's publication in a peer-reviewed journal.

VolitionRx Limited has entered into a Research License and Exclusive Commercial Option Rights Agreement with Werfen for its Nu.Q® NETs test aimed at managing Antiphospholipid Syndrome (APS). This agreement reflects Volition's strategy to collaborate with global leaders in diagnostics to advance their proprietary technologies. Positive preliminary findings in NETs detection could lead to improvements in APS management and patient outcomes. The partnership could also allow Werfen to expand its testing portfolio in APS diagnostics.

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

VolitionRx Limited (NYSE AMERICAN: VNRX) reported significant progress with its Nu.Q® Discover program, which focuses on epigenetic profiling and has captured a notable share of the market. The company anticipates continued growth in 2025, with multiple new contracts and strong demand for its assays as exploratory biomarkers in clinical trials. Nu.Q® Discover is currently serving over 20 clients globally and is expected to generate hundreds of thousands of dollars in revenue from major projects targeting cancer and other diseases. The success of the program enhances Volition's position in the competitive field of diagnostics and precision medicine.

-VNRX

Jul 14, 2025

VNRXGeneral

Nu.Q® Vet White Paper: Detecting cancer early to give dogs and their owners a brighter tomorrow.

The Nu.Q® Vet Cancer Test is a non-invasive blood test designed for early cancer detection in dogs, achieving 76% sensitivity and 97% specificity. It is intended for routine wellness checks and provides results quickly. The accompanying white paper includes case studies and testimonials highlighting its positive impact on pet health.

-VNRX

Jul 11, 2025

VNRXGeneral

The article discusses a study on plasma nucleosome concentrations in healthy cats, published in BMC Veterinary Research. This research is anticipated to facilitate a $5 million milestone payment for Volition following its publication. The study contributes to the development of the Nu.Q® Vet Cancer Test, marking a significant advancement in veterinary diagnostics.

-VNRX

May 19, 2025

VNRXPhases

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

VolitionRx Limited announced the publication of a study in BMC Veterinary Research that successfully detected nucleosomes in healthy cats. This advancement represents the first time such measurements have been reported for feline patients, which may facilitate cancer screening and monitoring in this species. The findings could lead to potential annual check-ups for a substantial portion of the U.S. cat population, estimated at over 60 million. VolitionRx aims to develop a product targeting feline lymphoma, the most common cancer in cats, thus expanding their diagnostic offerings beyond dogs and humans.

VolitionRX Limited has outlined a strategic plan to commercialize its Nu.Q® NETs product in the human diagnostics market, with a focus on addressing unmet needs in sepsis and coagulation. The company is in discussions with seven major international firms, which collectively have a market value of approximately $600 billion, to license its technology. Furthermore, Volition has already recorded revenue from its CE-marked Nu.Q® NETs product and is seeing interest from numerous hospital networks across Europe. This dual approach aims to leverage existing partnerships while expanding the clinical applications of the product to improve patient care worldwide.

The article serves as a guide for veterinarians on interpreting the results of the Nu.Q® Vet Cancer Test and outlines recommended post-test actions. It highlights the potential financial benefits tied to the publication of a related study in a peer-reviewed journal. Additionally, it mentions the launch of the first automated version of the test in collaboration with Fujifilm Vet Systems.

-VNRX

Apr 4, 2025

VNRXGeneral

How to submit a sample: Video

The article presents a video guide detailing the process of submitting a sample for the Nu.Q® Vet Cancer Test. It highlights the significance of this test in veterinary diagnostics and mentions related press releases about the test's development and potential financial benefits. The publication of a related study is anticipated to unlock a substantial milestone payment.

-VNRX

Apr 3, 2025

VNRXGeneral

▲ +6.2%on this newsshared move

VolitionRx Limited will showcase its Nu.Q® Vet Cancer Test at the 97th Annual Western Veterinary Conference in Las Vegas from March 2-5, 2025. The company aims to increase awareness and education about the test, which detects seven common cancers in dogs. Presentations will highlight the test's accessibility and rapid results, enhancing the capabilities of veterinary professionals. The conference is noted for being one of the largest veterinary gatherings in the U.S.

-VNRX

Feb 27, 2025

VNRXConferences/Events

▲ +9.5%on this newsshared move

VolitionRx Limited has announced a registered direct offering priced at up to $1.9 million, with the potential for an additional $2.7 million from warrants. The offering is directed towards certain directors, executive officers, and other investors. The company plans to use the proceeds for research and development, clinical studies, and commercialization of blood tests for diseases including cancers. The closing is expected on December 9, 2024, pending customary conditions.

-VNRX

Nov 26, 2024

VNRXGeneral

Lung cancer awareness month

Volition is advancing its Nu.Q® Cancer assays aimed at detecting and monitoring lung cancer. With November designated as lung cancer awareness month, the article highlights the disease's prevalence and risk factors. Volition's technology seeks to aid in early detection and treatment response monitoring, potentially improving patient outcomes.

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

VolitionRx Limited reported its financial results for Q3 2024, highlighting significant sales of its Nu.Q® Vet Cancer Tests and expansion into 17 countries. The company showcased promising data at a major symposium, indicating potential advancements in sepsis management. Despite a strong revenue increase, Volition faces challenges in cash usage and the need for licensing deals in the human diagnostics sector.

-VNRX

Nov 14, 2024

VNRXConferences/Events

▼ -5.8%on this newsshared move

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time Henderso

VolitionRx Limited announced its third-quarter financial results for 2024, showcasing substantial growth with a 96% year-to-date revenue increase. The company reported sales of over 110,000 Nu.Q Vet Cancer Tests and a significant expansion of its offerings, including access in 17 countries. Additionally, VolitionRx highlighted promising data on its Nu.Q NETs test, which may aid in sepsis management. The upcoming conference call will further discuss their operational progress and future plans.

-VNRX

Nov 8, 2024

VNRXConferences/Events

▲ +5.4%on this news· ran to +16% by day 3

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited has announced a conference call scheduled for November 15, 2024, at 8:30 a.m. Eastern Time to discuss its third quarter 2024 financial results and provide a business update. Key executives will participate to present insights on the company’s recent activities and future milestones. The event will also be accessible via a live audio webcast and will include options for a telephone replay. VolitionRx is committed to advancing epigenetic science to improve disease detection and monitoring.

-VNRX

Nov 6, 2024

VNRXGeneral

Volition Appoints Timothy I. Still as Chairman Henderson, Nevada

VolitionRx Limited has appointed Timothy I. Still as the Chairman of its Board of Directors, effective November 6, 2024. Mr. Still has over 35 years of experience in the medical diagnostics sector and previously served as President and CEO of Sense Biodetection. His expertise is anticipated to foster strategic growth and commercial viability for Volition, especially as the company focuses on developing innovative diagnostic technologies. Volition aims to enhance healthcare outcomes through their specialized blood tests for various diseases.

-VNRX

Nov 6, 2024

VNRXGeneral

Volition attended the European Society of Intensive Care Medicine Congress, showcasing their contributions to sepsis management. The event featured interviews with key medical professionals, including Professor Djillali Annane and Dr. Andrew Retter. Highlights included discussions on innovative treatments and insights from Volition's symposium on NETs.

-VNRX

Oct 9, 2024

VNRXConferences/Events

▼ -9.4%on this newsshared move

Volition to share new ‘NETs in sepsis management’ data insights at upcoming webinar

VolitionRx Limited is set to present new insights on its Nu.Q® NETs technology for sepsis management during an upcoming webinar. This follows the presentation of data at the ESICM LIVES 2024 congress, which involved over 3,000 patients. The webinar will feature discussions on the implications of elevated H3.1 nucleosomes in sepsis and their potential to predict organ failure.

-VNRX

Oct 9, 2024

VNRXConferences/Events

▼ -9.4%on this newsshared move

ESICM Symposium: ‘NETs: Casting a new light on sepsis management’ – Video

Volition hosted a symposium at ESICM 2024 titled 'NETs: Casting a new light on sepsis management'. The event was chaired by Prof. Djillali Annene and featured presentations from leading experts in intensive care medicine. Key topics included the clinical utility of nucleosome levels in septic acute kidney injury and the use of nanopore sequencing in understanding circulating DNA during ECMO.

-VNRX

Oct 9, 2024

VNRXConferences/Events

▼ -9.4%on this newsshared move

VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director, effective September 30, 2024. With over 20 years in the life sciences sector, Dr. Rubin will also serve on the Audit and Compensation Committees. Her experience includes leadership roles in various healthcare organizations, and she aims to support Volition's commercialization of its epigenetic solutions.

-VNRX

Sep 30, 2024

VNRXGeneral

Volition Appoints Dr. Ethel Rubin as an Independent Director Henderson, Nevada

VolitionRx Limited has appointed Dr. Ethel Rubin as an independent director and member of the Audit and Compensation Committees, effective September 30, 2024. Dr. Rubin has extensive experience in the life sciences sector, contributing to the launch of numerous commercial products and holding key leadership positions in various organizations. Her appointment is seen as a strategic move to enhance Volition's efforts in commercializing its epigenetic solutions, particularly its Nu.Q technology, which has potential applications in both animal and human health. Volition aims to advance diagnostic and monitoring solutions for major diseases.

-VNRX

Sep 26, 2024

VNRXGeneral

▼ -6.7%on this newsshared move

Capture-PCR™ video

Volition has introduced Capture-PCR™, a groundbreaking method for liquid biopsy that enables the physical isolation of tumor-derived ctDNA fragments from blood. This innovative approach allows for the extraction of cancer-derived ctDNA after eliminating normal background DNA, facilitating detection through a simple and cost-effective PCR test. The development marks a significant advancement in cancer diagnostics.

-VNRX

Sep 20, 2024

VNRXGeneral

Capture-PCR™ Product Brochure

The article presents a product brochure for Capture-PCR™, highlighting its relevance in cancer diagnostics. It also references related articles discussing the prognostic value of the Nu.Q® cancer test and research on chromatin accessibility in neutrophils linked to sepsis. The content encourages subscriptions for updates on Volition products.

-VNRX

Sep 19, 2024

VNRXConferences/Events

Becky Serieys shares her harrowing experience with sepsis, which developed after a flare-up of her Crohn's disease. Prompt medical intervention was crucial in her recovery, highlighting the challenges of diagnosing sepsis. Despite a long road to recovery, Becky emphasizes the importance of awareness and timely treatment for sepsis.

-VNRX

Aug 14, 2024

VNRXGeneral

VolitionRx Limited announced a registered direct offering of up to $21.5 million, which includes $7 million upfront and an additional $14.5 million from milestone-linked warrants. The offering, expected to close around August 12, 2024, involves the sale of 12,727,273 shares of common stock at an offering price of $0.55 per share. The proceeds will primarily be used for research and product development. H.C. Wainwright & Co. is the exclusive placement agent for this offering.

-VNRX

Aug 6, 2024

VNRXGeneral

How to use the Nu.Q® H3.1 Test

The article presents a short film created by Volition's R&D team that outlines the process for using the Nu.Q® H3.1 Test, which is designed for nucleosome quantification. It also invites readers to learn more about the technology and offers purchasing information for the H3.1 kits. Additionally, it references related articles on the prognostic value of the Nu.Q® cancer test.

-VNRX

Aug 6, 2024

VNRXConferences/Events

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited has scheduled a conference call for August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operational results for the second quarter of 2024. During the call, executives, including the CEO and Chief Financial Officer, will provide updates on significant events and milestones achieved in the past quarter. The company is concentrating on blood tests aimed at diagnosing and monitoring diseases, which could lead to improved patient outcomes.

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

VolitionRx Limited (VNRX) announced its participation at the Jefferies Global Healthcare Conference, with CEO Cameron Reynolds to present their innovative epigenetic technologies. Scheduled for June 5, 2024, the presentation aims to highlight the company's efforts in improving outcomes for patients with diseases like sepsis and cancer through earlier detection and monitoring. Attendees can arrange one-on-one meetings with Volition's executive team to learn more about their advancements in diagnostic testing.

-VNRX

May 22, 2024

VNRXGeneral

VolitionRx Limited announced its financial results for the first quarter of 2024, showcasing a 15% revenue increase year-over-year. The company plans a conference call to discuss these updates and upcoming milestones. Volition aims to achieve cash flow neutrality by 2025 through revenue growth and non-dilutive funding. However, the revenue growth from its Nu.Q Vet product line is slower than expected, prompting the company to implement cost reduction strategies.

-VNRX

May 8, 2024

VNRXConferences/Events

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited has announced a conference call scheduled for May 14, 2024, at 8:30 a.m. U.S. Eastern Time. The call will discuss the company's financial and operational results for the first quarter of 2024, as well as provide a business update. Key executives will be participating, including the President and Group CEO, along with senior finance and medical officers. This event reflects Volition's commitment to transparent communication regarding its progress in epigenetics and disease diagnostics.

-VNRX

Apr 30, 2024

VNRXGeneral

Martin Faulkes retires as Executive Chairman of Volition

Martin Faulkes, the Executive Chairman of Volition, is retiring after leading the company since its inception in 2010. Under his guidance, Volition has grown significantly, establishing itself as a multi-national entity with a strong focus on innovative epigenetic technology. Faulkes will officially retire at the Annual General Meeting in July, leaving a legacy of leadership and support for the company's mission.

-VNRX

Apr 29, 2024

VNRXConferences/Events

Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy

The poster presented by Pamart et al. at BSH 2024 discusses a novel method for isolating tumor-associated ctDNA fragments for liquid biopsy in acute myeloid leukemia (AML). This innovative approach aims to enhance prognostic capabilities and improve patient outcomes. The research highlights the potential of ctDNA analysis in cancer diagnostics.

The poster titled 'Immunoprecipitation of tumor associated ctDNA fragments for novel lung cancer liquid biopsy' was presented at the ELCC 2024 conference. This research focuses on utilizing ctDNA fragments for developing a liquid biopsy method aimed at enhancing lung cancer diagnostics. The findings may contribute to better prognostic tools in oncology.

-VNRX

Mar 21, 2024

VNRXConferences/Events

▼ -8.8%on this newsshared move

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

VolitionRx Limited has scheduled a conference call for March 26, 2024, to discuss its financial and operational results for the fourth quarter and full year of 2023. This call will also include a business update and will feature key executives from the company. The event highlights Volition's ongoing commitment to advancing epigenetics, including the development of cost-effective blood tests for early diagnosis and monitoring of various diseases.

-VNRX

Mar 20, 2024

VNRXGeneral

▼ -5.9%on this newsshared move

Volition & Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan – video

Volition Veterinary has partnered with Fujifilm Vet Systems to launch the Nu.Q® Vet Cancer Test in Japan. This supply agreement allows Fujifilm to offer cancer screening services for dogs through its network of laboratories. The initiative aims to enhance cancer detection in veterinary practices across Japan.

-VNRX

Mar 20, 2024

VNRXGeneral

▼ -5.9%on this newsshared move

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

VolitionRx Limited has entered into a supply agreement with Fujifilm Vet Systems to launch the Nu.Q® Vet Cancer Test for dogs in Japan. This collaboration allows Fujifilm Vet Systems to provide cancer screening services through its network of laboratories across the country. The test aims to facilitate early cancer detection and improve veterinary patient care. Volition expresses optimism about expanding its market presence in Asia and enhancing its offerings in veterinary diagnostics.

-VNRX

Mar 19, 2024

VNRXGeneral

▼ -5.9%on this newsshared move

Volition appoints Dr Andrew Retter as Chief Medical Officer

VolitionRx Limited has appointed Dr. Andrew Retter as Chief Medical Officer, effective April 1, 2024. Dr. Retter, an expert in Intensive Care and Haematology, will lead medical efforts to align Volition's research with patient needs. He has previously advised the company on its blood test technology aimed at detecting diseases associated with NETosis.

-VNRX

Mar 19, 2024

VNRXGeneral

Volition appoints Dr Andrew Retter as Chief Medical Officer Henderson, Nevada

VolitionRx Limited has appointed Dr Andrew Retter as Chief Medical Officer, effective April 1, 2024. Dr Retter, an expert in Intensive Care Medicine and Haematology, has been working with Volition in an advisory role since January 2022. His role will involve providing medical leadership to align the company's scientific and clinical efforts with patient needs. This appointment is seen as a significant step in Volition's aim to advance diagnostic solutions to improve patient outcomes.

-VNRX

Mar 14, 2024

VNRXGeneral

▼ -6.3%on this newsshared move

Pet Parents Brochure – The value of canine cancer screening

The article presents a brochure aimed at pet parents, emphasizing the significance of canine cancer screening for early detection of cancer in dogs. It introduces the Nu.Q® Vet Cancer Test, which is designed to assist pet owners in monitoring their dogs' health. The brochure aims to educate and encourage proactive health measures among pet owners.

-VNRX

Mar 8, 2024

VNRXConferences/Events

Genomeweb to Host Volition Webinar on Neutrophils.

Volition is sponsoring a GenomeWeb webinar on February 26th, focusing on the role of neutrophils in sepsis and organ injury. Led by Andrew Retter and Terry Kelly, the session will cover neutrophil functions and present new methodologies for studying these immune cells. The webinar aims to enhance understanding of neutrophils' roles in disease progression.

-VNRX

Feb 8, 2024

VNRXGeneral

Early cancer detection by plasma CTCF transcription factor analysis

VolitionRx has unveiled a novel liquid biopsy method for early cancer detection at the European Society for Medical Oncology congress. This technique allows for the physical isolation of tumor-derived ctDNA from blood, enabling rapid and cost-effective testing. Initial clinical trials show promising results in detecting various cancers, including leukemia and colorectal cancer, with high specificity rates.

-VNRX

Feb 6, 2024

VNRXConferences/Events

Webinar – Breakthrough Cancer Detection Method

Volition has announced a webinar to introduce a groundbreaking liquid biopsy blood test aimed at early cancer detection. This method was presented at the ESMO 2023 conference, highlighting its potential impact on cancer diagnostics. The webinar will provide insights into the innovative approach and its implications for patient care.

-VNRX

Feb 6, 2024

VNRXConferences/Events

▼ -5.8%on this newsshared move

A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer

The poster presented at ESMO 2023 by D. Pamart et al. introduces a novel immunoprecipitation/PCR method aimed at detecting plasma cfDNA fragments that are selectively occupied by CTCF in cancer. This innovative approach could enhance the prognostic value of cancer tests, particularly the Nu.Q® Cancer Test.

-VNRX

Feb 2, 2024

VNRXConferences/Events

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

VolitionRx Limited is set to participate in a webinar on February 13, 2024, to discuss recent advancements and ongoing studies related to its Nu.Q® NETs test for sepsis. The event will feature updates from key company executives and is aimed at increasing stakeholder awareness about the challenges of sepsis diagnosis and treatment. Additionally, the company will outline its future plans towards commercialization of its diagnostic technologies.

-VNRX

Jan 30, 2024

VNRXPhases

Nu.Q® NETs: New sepsis study at Guy’s & St Thomas NHS Foundation Trust.

VolitionRx's Nu.Q® NETs blood test is being evaluated in a new study at Guy's & St Thomas' NHS Foundation Trust. The EPICTETUS trial will assess its effectiveness in diagnosing and monitoring sepsis in 500 patients. The initiative has garnered significant media attention and support from health experts, highlighting its potential impact on patient outcomes.

-VNRX

Jan 30, 2024

VNRXGeneral

The article introduces Dr. Tom Butera, the CEO of Volition Veterinary, highlighting his career motivations and aspirations for the company. It emphasizes his leadership role and the advancements in veterinary cancer testing, particularly the Nu.Q® Vet Cancer Test. The article also mentions upcoming milestones related to the test's publication.

-VNRX

Jan 24, 2024

VNRXConferences/Events

KOL report: Nu.Q® NETs and sepsis

A recent KOL meeting hosted by Volition in September 2023 focused on the application of Nu.Q® NETs in sepsis care. Experts discussed how these biomarkers could improve patient management, facilitate early diagnosis, and guide treatment strategies. The potential for personalized medicine was also highlighted during the discussions.

-VNRX

Jan 23, 2024

VNRXConferences/Events

An interview with Professor Heather Wilson-Robles regarding NEW data presented at the VCS Conference 2021

Professor Heather Wilson-Robles, Chief Medical Officer of Volition Veterinary, discussed new data presented at the 2021 VCS virtual conference. This includes a manuscript submission for the Nu.Q® Vet Cancer Test in cats, which could lead to a $5 million milestone payment upon publication. Additionally, the first automated version of the Nu.Q® test was announced.

-VNRX

Jan 23, 2024

VNRXGeneral

Nu.Q® Cancer Brochure

The article presents information regarding the Nu.Q® Cancer Test and its prognostic value. It references related articles and publications but does not provide detailed insights into specific results or findings. The content appears to be promotional in nature, encouraging subscriptions for updates.

Volition Issues Business Review 2023

VolitionRx Limited has released its Business Review for 2023, highlighting notable achievements including the successful launch of the Nu.Q® Vet Cancer Test and completing the Q-Sub process with the FDA for Nu.Q® NETs. The company aims to enhance global access to its tests and has made significant advancements in early cancer detection methods. Volition's strategic initiatives are poised to strengthen its position in the diagnostics market. Despite these accomplishments, the company faces challenges such as market acceptance and competition in a rapidly evolving industry.

-VNRX

Jan 3, 2024

VNRXGeneral

▲ +13.7%on this newsshared move

Volition Business Review 2023

VolitionRx has made significant strides in 2023, including the expansion of its Nu.Q Vet Cancer Test through partnerships with IDEXX and Heska. New research highlights the test's potential for treatment monitoring in canine cancers. The company is also advancing its Nu.Q NETs test with a clear regulatory pathway in the U.S. and has introduced a novel cancer detection method, showcasing its commitment to innovation in diagnostics.

VolitionRx Limited has announced a conference call scheduled for November 15, 2023, to discuss its financial and operational results for the third quarter of 2023. The call will include an update on important events from the quarter and upcoming milestones, featuring key executives from the company. A live audio webcast of the call will also be accessible on Volition's investor relations page, with replay options available until November 29, 2023.

-VNRX

Nov 6, 2023

VNRXGeneral

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland

VolitionRx Limited and Veterinary Pathology Group have launched the Nu.Q® Vet Cancer Test in the UK and Ireland, aimed at early cancer detection in dogs. This non-invasive blood test is designed for high-risk dogs, such as older breeds and those with a family history of cancer. The collaboration emphasizes both companies' commitment to enhancing veterinary care and improving pets' quality of life.

-VNRX

Nov 6, 2023

VNRXGeneral

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland

VolitionRx Limited and the Veterinary Pathology Group have partnered to launch the Nu.Q® Vet Cancer Test across veterinary practices in the UK and Ireland. This innovative blood test aims for early detection and monitoring of cancer in dogs, particularly benefiting older dogs and breeds with higher cancer risks. The test can be easily integrated into standard veterinary procedures, enhancing preventive care and potentially improving treatment outcomes for pets. This initiative underscores both organizations' commitment to advancing animal healthcare.

-VNRX

Oct 27, 2023

VNRXConferences/Events

▼ -8.5%on this news

Breakthrough Cancer Detection Method Webinar – including Q&A session.

A webinar is scheduled to discuss a breakthrough method for cancer detection, featuring a Q&A session. This event aims to provide insights into the Nu.Q® Cancer Test, which shows promising prognostic value. Participants can expect to learn about advancements in cancer diagnostics and engage with experts.

-VNRX

Oct 25, 2023

VNRXConferences/Events

Differentiation of Malignant and Benign Lung Nodules using Epigenetically Modified Nucleosomes in Plasma

The presentation titled 'Differentiation of Malignant and Benign Lung Nodules using Epigenetically Modified Nucleosomes in Plasma' was delivered by Dr. Pei-Hsing Chen at ESMO 2023. It discusses a novel approach to enhance the diagnosis of lung nodules, potentially improving patient outcomes. The research emphasizes the use of epigenetically modified nucleosomes in plasma for better differentiation.

-VNRX

Oct 25, 2023

VNRXConferences/Events

A recent study published in the Annals of Intensive Care investigates the relationship between elevated levels of NET formation and nucleosome biomarkers and mortality rates in patients experiencing septic shock. The findings suggest that these biomarkers may serve as valuable prognostic indicators, potentially guiding treatment strategies. This research emphasizes the importance of monitoring these biomarkers in critical care settings.

-VNRX

Oct 16, 2023

VNRXConferences/Events

NETs-associated H3.1-nucleosome measurements in plasma correlate with severity of Alzheimer’s Disease progression

The poster presented by Candiracci et al. at the 33rd Alzheimer’s Europe Conference 2023 discusses the correlation between NETs-associated H3.1-nucleosome measurements in plasma and the severity of Alzheimer's Disease progression. This research highlights the potential of these measurements as a prognostic indicator for the disease. The findings contribute valuable insights into understanding Alzheimer's pathology.

-VNRX

Oct 16, 2023

VNRXConferences/Events

Volition Presents Three Cancer Detection Abstracts at ESMO 2023

VolitionRx Limited is set to present three significant abstracts at ESMO 2023, focusing on innovative cancer detection techniques. Among the presentations will be new data regarding lung cancer and glioblastoma. Dr. Dorian Pamart will showcase a novel detection method for plasma cfDNA fragments, while Dr. Pei-Hsing Chen will differentiate between malignant and benign lung nodules. In collaboration with the University of Namur, a study on nucleosome-based biomarkers for glioblastoma will also be presented.

-VNRX

Oct 14, 2023

VNRXConferences/Events

Liquid biopsies multi-modal analysis correlates with disease burden and response to treatment in paediatric cancer

The poster presented at SIOP 2023 discusses the correlation between liquid biopsies and disease burden in pediatric cancer. The study highlights how multi-modal analysis can provide insights into treatment responses. This research could pave the way for enhanced monitoring and personalized treatment strategies for young cancer patients.

-VNRX

Oct 13, 2023

VNRXConferences/Events

▲ +6.5%on this news· ran to +43% by day 3shared move

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

VolitionRx Limited has announced a proposed underwritten public offering of its common stock to raise funds for research, clinical studies, and product commercialization. The company will offer a 30-day option for underwriters to purchase additional shares. While the offering aims to support Volition's growth in developing innovative diagnostic tests, there are uncertainties about market conditions and the final terms of the offering. The use of proceeds includes working capital and potential acquisitions to further enhance product development.

-VNRX

May 11, 2023

VNRXGeneral

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring

VolitionRx Limited announced a study indicating that plasma nucleosome concentrations serve as a valuable metric for monitoring treatment and disease progression in dogs with hematopoietic cancers. Conducted at Texas A&M University, the research found that elevated nucleosome levels correlate with disease severity and are particularly useful in assessing treatment response. This advancement could enhance the management of canine lymphoma and other related cancers through improved tracking mechanisms.

-VNRX

May 10, 2023

VNRXConferences/Events

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time Henderson,

VolitionRx Limited reported its financial results for the first quarter of 2023, showcasing significant growth with a 381% increase in sales for its Nu.Q Vet Cancer Test. The company has entered into supply agreements with prominent industry players, enhancing its revenue potential. VolitionRx is also progressing towards the commercialization of its Nu.Q NETs test, with large-scale studies underway to support its FDA application. The company will discuss these updates in an upcoming conference call and Capital Markets Day, reinforcing its commitment to advancing cancer diagnostics.

-VNRX

May 5, 2023

VNRXConferences/Events

VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update

VolitionRx Limited announced a conference call scheduled for May 11, 2023, to discuss its first quarter financial results and provide a business update. The call will be hosted by key executives and will also include details about the company's Capital Markets Day on the same date. VolitionRx is developing innovative blood tests to help diagnose serious diseases, leveraging its proprietary Nu.Q® platform.

-VNRX

Apr 26, 2023

VNRXConferences/Events

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.

VolitionRx Limited is set to host a Capital Markets Day on May 11, 2023, at the NYSE. This hybrid event will include presentations from the executive team and notable experts in medicine, discussing corporate and commercial strategies, and clinical evidence. Attendees can join in-person or virtually, with the event aimed at informing investors about the latest developments in the company's healthcare solutions. The company specializes in epigenetics, particularly the Nu.Q technology used for diagnosing diseases.

▼ -11%on this newsshared move

VolitionRx Announces Appointment of David Kratochvil as Chief Financial Officer NAMUR, Belgium, August 17, 2015 - VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other condition

-VNRX

Aug 12, 2015

VNRXConferences/Events

SINGAPORE, Oct. 11 2011 /PRNewswire/ -- Volition, a life sciences company focused on developing blood-based diagnostic tests, has been advised by FINRA that the regulator has received the necessary documentation to announce a name change to VolitionRX Limited, and a change of sym

-VNRX

Oct 7, 2011

VNRXGeneral

Volition Announces Closure of Share Exchange Agreement

SINGAPORE, Oct. 7, 2011 /PRNewswire/ -- Singapore Volition Pte Limited ("Volition"), a life sciences company focused on developing blood-based diagnostic tests, today announces the closure of the Share Exchange Agreement with Standard Capital Corporation, a Delaware corporation c

Competitive Position

How VNRX ranks across every disease it competes in

Competitive Position is a premium feature

See how VNRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

VolitionRX Limited

$0.35

Cash Data

Overview

Company Description

Upcoming Catalyst

Past FDA Catalysts & PDUFA Decisions

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in VNRX

VNRX Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Company News

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Volition Advances Nu.Q® NETs Platform Towards Commercialization

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

VolitionRx Announces Collaboration with Sysmex

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

VolitionRx Announces Pricing of $4.6 Million Public Offering

VolitionRx Announces Pricing of $4.6 Million Public Offering $4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

New Study Highlights Elevated Circulating Nucleosome Levels Following Traumatic Injury

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time Henderson, Ne

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment

Cell Death White Paper, Nu.Q® Discover

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx krijgt 2,0 miljoen EUR aan niet-verwaterende financiering van regionale overheidsinstanties in BelgiëNederland - NederlandsUSA - EnglishFrance - Français

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx obtient un financement non dilutif de 2 millions d'euros auprès d'organismes publics régionaux en BelgiqueFrance - FrançaisUSA - English

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time Hender

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

Video: Transcription Factor DNA in Plasma New Data Revealed

Volition Announces Detection of Over 95% of Early-Stage Cancers

Capture-Seq™: Compelling proof-of-concept clinical data. A world first in isolating pure tumor-derived DNA from a liquid biopsy

ELCC 2026: Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation

Transcription Factor DNA analysis in plasma

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Veterinary resources – in clinic (UK/EU)

Sepsis Q&A with Volition CMO, Andrew Retter